216 related articles for article (PubMed ID: 31215825)
1. Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
Zheng L; Yang C; Xiang L; Hao Z
Biomarkers; 2019 Sep; 24(6):517-523. PubMed ID: 31215825
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
Lyu SQ; Yang YM; Zhu J; Wang J; Wu S; Zhang H; Shao XH; Ren JM
Platelets; 2020 Nov; 31(8):971-980. PubMed ID: 32546030
[TBL] [Abstract][Full Text] [Related]
3. Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
Wang X; Wang S; Yang J; Yu X; Liu L
Thromb Res; 2020 Sep; 193():130-138. PubMed ID: 32559569
[TBL] [Abstract][Full Text] [Related]
4. Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis.
Tang B; Wang X; Wang X; Liu L; Ma Z
J Pharm Pharm Sci; 2022; 25():9-23. PubMed ID: 34995471
[TBL] [Abstract][Full Text] [Related]
5. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
7. Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent.
Sánchez-Ramos J; Dávila-Fajardo CL; Toledo Frías P; Díaz Villamarín X; Martínez-González LJ; Martínez Huertas S; Burillo Gómez F; Caballero Borrego J; Bautista Pavés A; Marín Guzmán MC; Ramirez Hernández JA; Correa Vilches C; Cabeza Barrera J
Int J Cardiol; 2016 Dec; 225():289-295. PubMed ID: 27744205
[TBL] [Abstract][Full Text] [Related]
8. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.
Kheiri B; Osman M; Abdalla A; Haykal T; Pandrangi PV; Chahine A; Ahmed S; Osman K; Bachuwa G; Hassan M; Bhatt DL
Catheter Cardiovasc Interv; 2019 Jun; 93(7):1246-1252. PubMed ID: 30403317
[TBL] [Abstract][Full Text] [Related]
9. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Galli M; Benenati S; Capodanno D; Franchi F; Rollini F; D'Amario D; Porto I; Angiolillo DJ
Lancet; 2021 Apr; 397(10283):1470-1483. PubMed ID: 33865495
[TBL] [Abstract][Full Text] [Related]
10. The contribution of genotype-guided selection of P2Y
Wu Y; Yu D; Zhang L; Wu Y; Shu B; Ma L; Shi T
Eur J Clin Pharmacol; 2023 Sep; 79(9):1249-1259. PubMed ID: 37449992
[TBL] [Abstract][Full Text] [Related]
11. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
[TBL] [Abstract][Full Text] [Related]
12. Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI.
Liu J; Qin L; Xi S; Tong W; Yuan M; Peng L; Liu J; Wang X; Zhang Y; Yin T
Thromb Res; 2019 Jul; 179():87-94. PubMed ID: 31100633
[TBL] [Abstract][Full Text] [Related]
13. [Effects of clopidogrel resistence and CYP2C19 genotype on the clinical prognosis of patients with acute coronary syndrome undergoing percutaneous coronary intervention].
He CB; Li Q; Ye YC; Zhao XL; Tu CC; Zeng Y
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Sep; 48(9):765-771. PubMed ID: 32957760
[No Abstract] [Full Text] [Related]
14. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W
Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325
[TBL] [Abstract][Full Text] [Related]
16. Effects of the
Biswas M; Sukasem C; Khatun Kali MS; Ibrahim B
Pharmacogenomics; 2022 Feb; 23(3):207-220. PubMed ID: 35042400
[TBL] [Abstract][Full Text] [Related]
17. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
AlMukdad S; Elewa H; Al-Badriyeh D
J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
[TBL] [Abstract][Full Text] [Related]
18. Genotype-guided antiplatelet treatment versus conventional therapy: A systematic review and meta-analysis.
Zhang H; Xiang Q; Liu Z; Mu G; Xie Q; Zhou S; Ma L; Wang Z; Hu K; Wang Z; Cui Y
Br J Clin Pharmacol; 2021 May; 87(5):2199-2215. PubMed ID: 33140858
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention.
Williams AK; Klein MD; Martin J; Weck KE; Rossi JS; Stouffer GA; Lee CR
Circ Genom Precis Med; 2019 Feb; 12(2):e002441. PubMed ID: 30779635
[No Abstract] [Full Text] [Related]
20. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
